Overview of Segmentation, Market Dynamics, and Competitive Landscape in the MSI-H and dMMR Market

The MSI-H and dMMR market is rapidly evolving, driven by advancements in precision oncology and immunotherapy. With an increasing number of innovative treatments and diagnostic tools emerging, this sector is set to experience substantial growth over the coming years. Let's explore the current market size projections, key players, noteworthy collaborations, upcoming trends, and segmentation details shaping this important healthcare field.

Significant Growth Anticipated in the MSI-H and dMMR Market Size by 2030
The MSI-H and dMMR market is projected to expand dramatically, reaching a value of $21.13 billion by 2030. This represents a compound annual growth rate (CAGR) of 22.7%, highlighting robust momentum throughout the forecast period. Several factors contribute to this surge, including wider adoption of precision oncology approaches, increased use of genomic testing in cancer treatment, expansion of immunotherapy indications, growing investments in biomarker research, and mounting clinical evidence supporting tumor-agnostic therapies. Key trends expected to influence this growth include greater uptake of immunotherapy for MSI-H and dMMR tumors, enhanced use of companion diagnostics for patient selection, heightened focus on tumor-agnostic cancer therapies, broader implementation of combination immunotherapy regimens, and more awareness surrounding biomarker-driven oncology practices.

Download a free sample of the msi-h and dmmr market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24324&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Companies Driving the MSI-H and dMMR Market Forward
The MSI-H and dMMR landscape features prominent players such as Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca PLC, Bristol-Myers Squibb Company, GSK plc., Takeda Pharmaceutical Company, Incyte Corporation, Exact Sciences Corp., BeiGene LTD., Summit Therapeutics Inc., Tempus Labs Inc., Guardant Health, NeoGenomics Laboratories Inc., Promega Corporation, Caris Life Sciences, and Owkin. A notable development occurred in December 2023 when Owkin Inc., a France-based firm specializing in AI-driven drug discovery and precision medicine, teamed up with Merck & Co. Inc. to develop AI-powered digital pathology diagnostics aimed at improving MSI-H testing rates in the EU market. This collaboration targets multiple cancer types, including endometrial, gastric, small intestinal, and biliary cancers. By leveraging artificial intelligence, the partnership seeks to enhance diagnostic accuracy, streamline laboratory processes, and better match patients with suitable therapies. Merck & Co. Inc. is also known for providing KEYTRUDA (pembrolizumab) to adult and pediatric patients with unresectable or metastatic MSI-H cancer.

Emerging Therapeutic Trends in the MSI-H and dMMR Market
Companies in the MSI-H and dMMR market are increasingly focusing on developing innovative therapies, particularly combination treatments, to improve patient outcomes. Combination therapy typically involves using two or more treatment approaches-often immunotherapy agents such as checkpoint inhibitors, or pairing immunotherapy with chemotherapy, targeted therapy, or radiation. This strategy aims to boost treatment effectiveness, overcome resistance mechanisms, and enhance survival rates for patients with tumors characterized by high microsatellite instability or deficient mismatch repair mechanisms.

View the full msi-h and dmmr market report:
https://www.thebusinessresearchcompany.com/report/msi-h-and-dmmr-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

A significant milestone was reached in April 2025 when Bristol-Myers Squibb Company received FDA approval for combining nivolumab (Opdivo) and ipilimumab (Yervoy) as a first-line treatment for metastatic colorectal cancer (mCRC) exhibiting MSI-H or dMMR features. This approval represents a breakthrough for this difficult-to-treat cancer subtype by offering a new treatment that targets multiple biological pathways, thereby improving survival chances and response rates. It addresses critical unmet medical needs within this patient group and signals promising advancements in MSI-H and dMMR cancer care.

Detailed Segmentation of the Global MSI-H and dMMR Market
The MSI-H and dMMR market is categorized across several dimensions for in-depth analysis:
1) Treatment Type: Immune Checkpoint Inhibitors (ICIs), Combination Therapy
2) Indication: Endometrial, Gastric, Colorectal Cancer, Small Intestine Cancer, Cervical Cancer, and Other Indications
3) Stage: Early Stages, Advanced Stages
4) End User: Hospitals, Oncology Clinics, Research Institutions, Homecare Settings

Further subcategories include:
- Within Immune Checkpoint Inhibitors (ICIs): Programmed Cell Death Protein 1 Inhibitors, Programmed Cell Death Ligand 1 Inhibitors, and Cytotoxic T-Lymphocyte Antigen 4 Inhibitors
- Within Combination Therapy: Immune Checkpoint Inhibitor combined with Chemotherapy, Targeted Therapy, Radiation Therapy, or other Immunotherapies

This segmentation provides a comprehensive view of treatment modalities, target patient populations, and delivery channels shaping the MSI-H and dMMR market's growth trajectory.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.